At a glance
ClinicalIndex Comparison Record- ✓Relapsed CD20+ B-cell NHL (diffuse large cell, mantle cell, or transformed histologies) within 5 years, aggressive histology, not responding to or relapsed after initial chemotherapy
- ✓Candidate for platinum-containing regimen if treated off-study
- ✓Measurable disease ≥1.5 × 1.5 cm
- ✓Tumor biopsy ≤6 weeks prior confirming CD20+ histology
- ✕HIV infection
- ✕Prior chemotherapy or biologic therapy ≤4 weeks prior to registration
- ✕Persistent acute toxicities from prior chemotherapy or biologic therapy
- ✕Active malignancies other than NHL
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma
In Brief
A Phase 2 clinical trial evaluating Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) for Lymphoma. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
Study Details
Timeline
Interventions
rituximab 375 mg/m2 IV Weekly x 4 1 cycle only dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles